

Index

A

- ACTA2*, smooth muscle vasculopathy mutations, 163
- ACTC1*, cardiomyopathy mutation, 141
- Activin A, 72
- ADAMTS1, 96
- Aortic aneurysm
 - gene mutations
 - extracellular matrix, 157
 - table, 155–156
 - Loeys–Dietz syndrome and transforming growth factor- β signaling mutations, 159–160
- Marfan syndrome
 - aneurysm and gene mutations, 154, 156
 - transforming growth factor- β signaling, 157–159
- pathophysiology, 153–154
- prospects for study, 165
- smooth muscle vasculopathy, 162–164
- transforming growth factor- β signaling
 - canonical versus noncanonical signaling, 160–162
 - high versus low, 164–165
- Aortic arch, artery patterning, 59–60
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
 - clinical features and gene mutations, 139
 - human pluripotent stem cell models, 193, 198
- Arterial pole, progenitor cells, 5–6
- ARVC. *See* Arrhythmogenic right ventricular cardiomyopathy
- ASD. *See* Atrial septal defect
- Atrial septal defect (ASD), gene mutations, 109, 111–112, 122
- Atrioventricular septal defect (AVSD)
 - copy number variation, 125–126
 - gene mutations, 109, 111–112, 123
- AVSD. *See* Atrioventricular septal defect

B

- Ballooning morphogenesis, biomedical impact, 21
- β -catenin
 - mesoderm differentiation, 70–71
 - venous pole development, 18
- BMPs. *See* Bone morphogenetic proteins
- Bone morphogenetic proteins (BMPs)
 - cardiogenic mesoderm precursors, 52–55
 - chamber morphogenesis, 20

- endothelial cell differentiation from stem cells, 72
- epicardium formation, 55
- second heart field development, 18, 20
- venous pole development, 7, 18
- Boolean models, heart development, 36, 38
- Brachyury, 52

C

- Cardiac crescent. *See* First heart field
- Cardiac neural crest cell (CNCC)
 - aortic arch artery patterning and outflow tract septation, 59–60
 - induction and migration signaling, 57–59
 - progenitor cells, 50–52, 57
 - valve development, 90, 92
- Cardiac stem cell. *See* Human pluripotent stem cell
- Cardiomyocyte
 - regenerative models
 - cell lines, 172–173
 - coculture, 171–172
 - microfluidic systems, 172
 - overview, 170–171
 - primary cells, 173
 - stem/progenitor cell differentiation, 173–174
 - three-dimensional culture, 171
 - two-dimensional culture, 171
 - stem cell differentiation in vitro, 69–71
 - stem cell models of heart disease. *See* Human pluripotent stem cell
- Cardiomyopathy
 - classification, 134
 - gene mutations
 - arrhythmic syndromes, 140
 - arrhythmogenic right ventricular cardiomyopathy, 139
 - dilated cardiomyopathy, 138–139
 - discovery, 134–135
 - hypertrophic cardiomyopathy, 135
 - left ventricular compaction, 139–140
 - novel variants in general population, 141–142
 - restrictive cardiomyopathy, 140
 - table, 136–138
 - therapy guidance, 147
 - genetic models
 - development, 142–143
 - functional evaluation

Index

- Cardiomyopathy (*Continued*)
 induced pluripotent stem cells, 145
 zebrafish, 145–146
 genetic testing, 147
 human pluripotent stem cell models, 192
 nongenetic factors, 143–145
 overlapping phenotypes and genes, 140–141
 overview, 133–134
 prospects for study, 147–148
 reprogramming for regenerative medicine
 clinical prospects, 223
 fibroblast reprogramming, 218–219
 functional comparison to cardiomyocytes,
 219–220
 mouse studies, 220–222
 overview, 217–218
Catecholaminergic polymorphic ventricular
 tachycardia (CPVT), human
 pluripotent stem cell models,
 191–192, 198
Cathepsin K, valve remodeling, 95
Chamber morphogenesis
 epicardium-derived cells, 55, 57
 initiation, 20–21
CHD. *See* Congenital heart disease
Chromatin modification. *See* Epigenetics
Clopidogrel, pharmacogenomics, 230–231
CNCC. *See* Cardiac neural crest cell
CNV. *See* Copy number variation
COL3A1, Marfan syndrome mutations, 154
COL6A1, modifier gene in congenital heart disease, 123
COL6A2, modifier gene in congenital heart disease, 123
Compact layer, cell lineages, 8
Conduction system, cell lineages, 8–9
Congenital heart disease (CHD). *See also specific genes*
 copy number variation, 124–127
 de novo mutations, 124
 epidemiology, 107, 121
 genome-wide association study of common variants,
 126, 128–129
 modifier genes, 115, 122–124
 monogenic gene mutations, 60, 107–114
 noncoding mutations, 129–130
 phenotypic variability, 115–116
 prospects for study
 monogenic disease, 116
 polygenic disease, 130–131
 TBX mutations, 114–115
Copy number variation (CNV), congenital heart
 disease, 124–126
CPVT. *See* Catecholaminergic polymorphic ventricular
 tachycardia
CRELD1, modifier gene in congenital heart disease, 115,
 123
CRISPR/Cas9 technology, genome-wide screening of
 diploid stem cells, 75–78, 278
CYP2C9, 229–230
CYP2C19, 230–231
D
DCM. *See* Dilated cardiomyopathy
DES, cardiomyopathy mutation, 140
DICER, 41
DiGeorge syndrome, 5, 20, 60, 11
Dilated cardiomyopathy (DCM)
 clinical features and gene mutations, 138–139
 human pluripotent stem cell models, 192
DNA methylation. *See* Epigenetics
Down syndrome (DS), congenital heart disease,
 114–115, 123, 126
Drug discovery and development
 animal models, 269–272
 cardiovascular disease mortality, 263–264
 clinical trials, 272–274
 ischemia reperfusion injury, 270
 portfolio decisions for target selection, 266–269
 regenerative models
 drug-screening tools, 252–253
 human pluripotent stem cell heart disease
 models, 253–255
 overview, 251–252
 prospects, 259
 regenerative therapy
 overview, 256
 mesenchymal stem cells, 256–257
 paracrine factors and developmental pathway
 modulators, 257–259
 toxicology and safety assays, 255
 research and development overview, 264–266
DS. *See* Down syndrome
E
EB. *See* Embryoid body
EC. *See* Endothelial cell
ECM, *see* Extracellular matrix
ELN
 aortic aneurysm gene mutations, 157
 modifier gene in congenital heart disease, 122–123
Embryoid body (EB), cardiomyocyte differentiation in
 vitro, 70
Embryonic stem cell. *See* Human pluripotent stem cell
EMT. *See* Epithelial-to-mesenchymal transition
ENCODE, 32, 120, 130
Endocardium, development, 9–10
Endothelial cell (EC)
 heart valve
 functions, 86–87
 fusion, 94–95
 human pluripotent stem cell differentiation, 196–197
 stem cell differentiation in vitro, 71–72

- Endothelin, 59
- Epicardium
 - development, 10
 - proepicardium. *See* Proepicardium
- Epicardium-derived cell (EPDC)
 - cardiac injury response, 257
 - heart development overview, 55, 57
 - valve development, 90
- Epigenetics
 - gene regulatory network and cell fate attractors, 28–29
 - heart development regulation, 38–40
- Epithelial-to-mesenchymal transition (EMT)
 - epicardium, 55
 - heart valve, 88–89
 - Mesp1 activation, 2
- ERK1, 162
- ERK2, 162
- Erv2*, endocardium development, 9
- ETS2, fibroblast reprogramming into cardiac progenitors, 202
- Extracellular matrix (ECM)
 - aortic aneurysm gene mutations, 157
 - heart valve
 - overview, 85–86
 - remodeling, 96
 - scaffold materials, 241
- F**
- FANTOM, 32
- FBLN2*, modifier gene in congenital heart disease, 123
- FBN1*
 - aortic aneurysm gene mutations and alleles, 157–158
 - Marfan syndrome mutations, 154, 156–157
- FGFs. *See* Fibroblast growth factors
- FHF. *See* First heart field
- Fibrillin-1. *See* *FBN1*
- Fibroblast, reprogramming into cardiac progenitors, 202, 219
- Fibroblast growth factors (FGFs)
 - cardiogenic mesoderm precursors, 52–55
 - chamber morphogenesis, 20, 59
 - endothelial cell differentiation from stem cells, 72
 - epicardium formation, 55
 - Fgf10*, head skeletal muscle expression, 19
 - second heart field development, 5–6
 - venous pole development, 7
- Fibulin-4, aortic aneurysm role, 157–158
- Fibulin-5, aortic aneurysm role, 157
- First heart field (FHF)
 - attractor states, 37
 - developmental overview, 29–30, 50
 - markers, 3
 - mesoderm progenitors, 52, 54–55
 - progenitor isolation in mice, 68
 - signal gating of enhancer function, 36, 38
- FOXC2, 18
- FRZB*, modifier gene in congenital heart disease, 123
- G**
- GATA4
 - cardiac kernel, 31
 - fibroblast reprogramming, 219
 - gene mutation and congenital heart disease, 60, 111–114
 - heart tube development, 16
 - mesoderm progenitors, 54
 - modifier genes, 115
 - subpharyngeal cardiac progenitor cell proliferation and differentiation, 18
- GATA5*, modifier gene in congenital heart disease, 123
- Gene regulatory network (GRN)
 - epigenetic memory and cell fate attractors, 28–29
 - network view of biology, 29
 - overview, 26
 - regulation in heart development
 - Boolean models of heart development, 36, 38
 - Drosophila* model, 34–35
 - enhancers
 - functions, 33–34
 - machine learning for classification, 34
 - signal gating, 35–36
 - prospects for study, 42–43
 - restriction of developmental potential and cell fate, 28
- Genome editing, human pluripotent stem cells, 72–73
- GLA*, cardiomyopathy mutation, 135
- GLP-1. *See* Glucagon-like peptide-1
- Glucagon-like peptide-1 (GLP-1), 255
- GRN. *See* Gene regulatory network
- H**
- HCM. *See* Hypertrophic cardiomyopathy
- HCN4, cardiac crescent marker, 3
- Heart valve
 - cell types
 - endothelial cell, 86–87
 - interstitial cell, 87
 - development
 - overview, 87–88
 - patterning and epithelial-to-mesenchymal transition, 88–89
 - extracellular matrix, 85–86
 - morphogenesis
 - endothelial cell fusion, 94–95
 - lineage tracing
 - atrioventricular valves, 90–93
 - SL valves, 95–94

Index

- Heart valve (*Continued*)
overview, 89–90
postfusion morphogenesis, 95
perfusion of mesenchyme structures, 90
prospects for study, 99–100
remodeling
extracellular matrix, 96
lineage diversification, 95–96
structure and function, 83–85
tissue engineering
challenges, 99
engineering in situ with scaffolds, 98–99
overview, 96–97
scaffolds, 97–98
stem cell sources, 97
- Hedgehog, second heart field development, 18, 20
- Hey1*, heart valve development, 89
- Hey2*, heart valve development, 89
- Histone modification. *See* Epigenetics
- hPSC. *See* Human pluripotent stem cell
- Human pluripotent stem cell (hPSC)
cardiomyocyte differentiation in vitro, 69–71
cardiomyopathy evaluation with induced pluripotent stem cells, 145
endothelial cell differentiation in vitro, 71–72
generation, 69
genome editing, 72–73
genome-wide screening
diploid cells
CRISPR/Cas9 technology, 75–78
prospects for cardiogenesis studies, 78
haploid cells, 73–75
- heart disease models
cardiovascular progenitor cell differentiation
advances and challenges, 189
cardiomyocyte heterogeneity, 195–196
cardiomyocyte maturation, 189
interline variability in cardiac differentiation, 196
diseases, 190–194, 198
embryonic stem cell models, 197–198
induced pluripotent stem cell models, 197–198
limitations, 202–203
prospects
complex disease modeling, 198–199
personalized medicine, 201
progenitor purification and lineage marking, 199–200
tissue engineering, 200–201, 243–246
somatic cell reprogramming, 201–202
vascular smooth muscle cell and endothelial cell differentiation, 196–197
properties, 187–189
regenerative medicine, 60–61
regenerative medicine. *See* Regenerative models
- Hutchinson–Gilford progeria, human pluripotent stem cell models, 194
- Hypertrophic cardiomyopathy (HCM)
clinical features and gene mutations, 135, 142, 163
human pluripotent stem cell models, 192
- I**
- IL-6. *See* Interleukin-6
- Induced pluripotent stem cell. *See* Human pluripotent stem cell
- Interleukin-6 (IL-6), inhibitors, 271
- Internal ribosome entry site (IRES), 72
- Interstitial cell, heart valve, 87
- Interventricular septum, cell lineages, 8
- IRES. *See* Internal ribosome entry site
- Ischemia reperfusion injury, 270
- Isl1*
arterial pole development, 5–6
cardiac kernel, 31
conduction system, 9
endocardium development, 9
epicardium development, 10
head skeletal muscle expression, 19
mesoderm progenitors, 54
second heart field expression, 4, 68
subpharyngeal cardiac progenitor cell proliferation and differentiation, 18
venous pole development, 7
- J**
- JNK1, 162
- K**
- Kabuki syndrome, 124
- L**
- LAMP2*, cardiomyopathy mutation, 135
- Latent transforming growth factor- β -binding proteins (LTBPs), 158
- LDS. *See* Loews–Dietz syndrome
- Left ventricular compaction (LVNC), clinical features and gene mutations, 139–140
- LEOPARD syndrome, human pluripotent stem cell models, 193, 198
- LHX3a, cardiac kernel, 31
- LMNA*, cardiomyopathy mutation, 134, 138, 141
- Loews–Dietz syndrome (LDS), transforming growth factor- β signaling mutations, 159–160
- Long intergenic noncoding RNA, heart development regulation, 42
- Long noncoding RNA, heart development regulation, 41

Long QT syndrome (LQTS)
 drug development, 269
 human pluripotent stem cell models, 190–191, 198
LQTS. *See* Long QT syndrome
LTBPs. *See* Latent transforming growth factor- β -
 binding proteins
LVNC. *See* Left ventricular compaction

M

MAML3, common variants, 128–129
Marfan syndrome
 aneurysm and gene mutations, 154, 156
 mitogen-activated protein kinase signaling, 162
 transforming growth factor- β signaling, 157–159,
 161
Mef2C
 cardiac kernel, 31
 enhancer function, 33
 fibroblast reprogramming, 219
 subpharyngeal cardiac progenitor cell proliferation
 and differentiation, 18
MEIS1, 40
MEIS2, 40
Mesenchymal stem cell (MSC)
 heart valve engineering, 97
 regenerative medicine, 256–257
Mesoderm progenitors
 early vertebrate cardiogenesis, 51–52
 induction, 52
MESP1
 cardiac kernel, 31
 cardiac precursor cell expression, 5
 conduction system, 8–9
 delamination role, 2
 fibroblast reprogramming into cardiac progenitors,
 202
 head skeletal muscle expression, 5
 heart tube development, 16
 mesodermal progenitors, 52
MESP2, delamination role, 2
Messenger RNA. *See* Synthetic chemically modified
 messenger RNA
Mibefradil, 271
MicroRNA
 cardiomyopathy studies, 143–144
 heart development regulation, 40–41
Mixl1, 73, 238
MLC. *See* Myosin light chain
modRNA. *See* Synthetic chemically modified messenger
 RNA
MSC. *See* Mesenchymal stem cell
MYBPC3, cardiomyopathy mutation, 135, 142
Myf5, 5
MYH11, smooth muscle vasculopathy mutations, 163
MYH7, cardiomyopathy mutation, 134–135, 139–142

MYL2, 140, 220
MYL3, 140
Myocardial tissue engineering. *See* Tissue engineering
MyoD, 5, 19, 218
Myosin light chain (MLC), modifications and smooth
 muscle vasculopathy, 162

N

Neuregulin-1, 177
NKX2-5
 conduction system, 9
 endocardium development, 9
 enhancer function, 33, 36
 epicardium development, 10
 fluorescent protein fusion, 73
 gene mutation and congenital heart disease, 60,
 108–111
 heart tube development, 16
 mesoderm progenitors, 54, 238
 modifier genes, 115
 subpharyngeal cardiac progenitor cell proliferation
 and differentiation, 18
 venous pole development, 7
Notch, chamber morphogenesis, 20
NOTCH1
 cardiomyopathy mutation, 144
 valve development, 95

O

OCT4, cardiac kernel, 31
OFT. *See* Outflow tract
Outflow tract (OFT)
 gene mutations and defects, 5
 septation, 59–60

P

PE. *See* Proepicardium
PEO. *See* Proepicardial organ
Personalized medicine
 cardiovascular risk prediction, 227–229
 genome-wide association studies, 226–227
 human pluripotent stem cell heart disease models,
 201
 next-generation sequencing, 227
 pharmacogenomics
 clopidogrel, 230–231
 statins, 231
 warfarin, 229–230
 prospects, 231–232
Pharmacogenomics. *See* Personalized medicine
Pitx2
 cardiac patterning, 19
 heart valve development, 88

Index

- PLN*, cardiomyopathy mutation, 141
Pol II. *See* RNA polymerase II
Pompe's disease, human pluripotent stem cell models, 193
PRDM16, cardiomyopathy mutation, 139
PRKAG2, 135
Proepicardial organ (PEO), epicardium development, 10
Proepicardium (PE)
 chamber maturation and coronary vessel formation, 55, 57
 epicardium-derived cells, 55, 57
 induction, 55
 origin and fates, 55–56
 progenitor cells, 51
PTPN11, common variants, 129
Pum1, 74
- R**
- RANKL, valve remodeling, 95
RCT. *See* Reverse cholesterol transport
Regenerative models
 animal models
 amphibians, 176
 humans, 179
 large animals, 178
 noncardiac models, 174
 small mammals, 176–178
 snake, 176
 species comparison of heart characteristics, 176–178
 zebrafish, 175–176
 cell models
 cardiomyocyte, 170–171
 cell lines, 172–173
 coculture, 171–172
 microfluidic systems, 172
 primary cells, 173
 stem/progenitor cell differentiation, 173–174
 three-dimensional culture, 171
 two-dimensional culture, 171
 computational models, 170
 drug discovery and development
 drug-screening tools, 252–253
 human pluripotent stem cell heart disease models, 253–255
 overview, 251–252
 prospects, 259
 regenerative therapy
 overview, 256
 mesenchymal stem cells, 256–257
 paracrine factors and developmental pathway modulators, 257–259
 toxicology and safety assays, 255
 overview, 169–170
 schematic of complexity, 170
 tissue models, 174
 whole heart/ex vivo models, 174
Restrictive cardiomyopathy, clinical features and gene mutations, 140
Reverse cholesterol transport (RCT), 255
Right ventricle (RV), gene mutations and defects, 5
RNA polymerase II (Pol II), epigenetic regulation of heart development, 38, 40
RV. *See* Right ventricle
- S**
- SCF. *See* Stem cell factor
SCN10A, 34
SCN5A, 34
SDF-1, cardiac regeneration studies, 258
Second heart field (SHF)
 attractor states, 37
 developmental overview, 29–30, 50
 diversity encoding, 18–19
 gene mutations and disease, 19–20
 Isl1, 4–6, 68
 mesoderm progenitors, 52, 54–55
 progenitor cells, 5–6, 16–17
 progenitor isolation in mice, 68
 signal gating of enhancer function, 36, 38
Selector gene hypothesis, 26–28
SGS. *See* Shprintzen–Goldberg syndrome
SHE. *See* Second heart field
Shprintzen–Goldberg syndrome (SGS), 165
Sinus venosus, formation, 7
SKI, 165
SLCO1B1, 231
SMAD2, de novo mutations, 124
SMAD3, Loeyes–Dietz syndrome mutations, 159–160, 164
SMAD4, aortic aneurysm gene mutations, 160
SMARCD3, heart tube development, 16
Smooth muscle cell, human pluripotent stem cell differentiation, 196–197
Smooth muscle vasculopathy (SMV), aortic aneurysm, 162–164
SMV. *See* Smooth muscle vasculopathy
SSEA-1, 178
Statins
 drug discovery and development, 263, 272
 pharmacogenomics, 231
Stem cell. *See* Human pluripotent stem cell; Mesenchymal stem cell
Stem cell factor (SCF)
 cardiac regeneration studies, 258
 endothelial cell differentiation from stem cells, 72

- Synthetic chemically modified messenger RNA (modRNA)
advantages and limitations versus conventional gene transfer, 211
heart progenitor cell fate studies, 210–211
immune surveillance escape for protein expression, 208–209
overview, 207–208
therapeutic application, 211, 213, 279
transfection of cardiac and skeletal muscle cells, 209–210
- Systems biology
genome-wide technology, 31–32
network view of biology, 29
overview, 25–26
- T**
- TALENs, 75, 146, 197
TB4, cardiac regeneration studies, 258–259
TBX1
arterial pole development, 5–6
defects and heart development, 5, 20
gene mutation and congenital heart disease, 60, 114–115
head skeletal muscle expression, 19
subpharyngeal cardiac progenitor cell proliferation and differentiation, 18
TBX2
chamber morphogenesis, 21
heart valve development, 89
TBX3, chamber morphogenesis, 21
TBX5
cardiac crescent marker, 3
cardiac kernel, 31
chamber morphogenesis, 21
fibroblast reprogramming, 219
gene mutation and congenital heart disease, 60, 114
heart tube development, 16
noncoding mutations, 129–130
second heart field expression, 5, 238
TBX6, cardiac kernel, 31
Tbx18, epicardium development, 10
TBX20
cardiac kernel, 31
chamber morphogenesis, 21
Tetralogy of Fallot (TOF), 121, 125, 129
TGF- β . *See* Transforming growth factor- β
Timothy syndrome, human pluripotent stem cell models, 191
Tissue engineering. *See also* Regenerative models; *specific tissues*
functional myocardium applications
drug testing
advantages and limitations, 243
cardiotoxicity, 242
proarrhythmic actions, 242–243
human pluripotent stem cell heart disease models, 200–201, 243–246
heart cells, 237–239
overview, 235–237
scaffold materials, 240–242
TOF. *See* Tetralogy of Fallot
TPM1, cardiomyopathy mutation, 140
Trabeculated myocardium, cell lineages, 8
Transforming growth factor- β (TGF- β), aortic aneurysm signaling
canonical versus noncanonical signaling, 160–162
high versus low levels of signaling, 164–165
Loeys–Dietz syndrome defects, 159–160
Marfan syndrome, 157–159, 161
TTN, cardiomyopathy mutation, 139, 141–142
- V**
- Valve. *See* Heart valve
Vascular endothelial growth factor (VEGF)
cardiac regeneration studies, 258–259
endothelial cell differentiation from stem cells, 72
synthetic chemically modified messenger RNA studies of cell fate, 210–212
VEGF. *See* Vascular endothelial growth factor
VEGFR2
cardiac crescent and linear heart tube formation, 52, 54–55
mesoderm progenitors, 54
Venous pole, progenitor cells, 6–8
Ventricular septal defect (VSD)
gene mutations, 108–109, 111–112, 122
phenotypic variability, 115–116
VKORC1, 229–230
VSD. *See* Ventricular septal defect
- W**
- Waddington landscape, 26–27
Warfarin, pharmacogenomics, 229–230
WES. *See* Whole exome sequencing
Whole exome sequencing (WES), cardiomyopathy studies, 141, 147a
Williams syndrome, human pluripotent stem cell models, 194
WNT
cardiogenic mesoderm precursors, 52
venous pole development, 18
Wt1, epicardium development, 10, 55